Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | THRB | P10828 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL367880 | 0.86 | KDM4E (0.59) | KDM4EALDH1A1MAPTCYP3A4GAA | |
| SCHEMBL28062236 | 0.86 | ALDH1A1 (0.59) | KDM4EALDH1A1MAPTCYP3A4GAA | |
| SCHEMBL7100581 | 0.85 | ALDH1A1 (0.53) | KDM4EALDH1A1MAPTCYP3A4GAA | |
| Nonanol SCHEMBL7761218 | 0.84 | PPARA (0.43) | KDM4EALDH1A1MAPTCYP3A4GAA | |
| SCHEMBL7320062 | 0.84 | MAPT (0.42) | KDM4EALDH1A1MAPTCYP3A4GAA | |
| SCHEMBL182142 | 0.84 | ALDH1A1 (0.57) | KDM4EALDH1A1MAPTCYP3A4GAA | |
| SCHEMBL8477518 | 0.84 | KDM4E (0.57) | KDM4EALDH1A1MAPTCYP3A4GAA | |
| SCHEMBL34474732 | 0.84 | KDM4E (0.57) | KDM4EALDH1A1MAPTCYP3A4GAA | |
| SCHEMBL5374527 | 0.82 | ALDH1A1 (0.55) | KDM4EALDH1A1MAPTCYP3A4GAA | |
| SCHEMBL21352086 | 0.82 | KDM4E (0.55) | KDM4EALDH1A1MAPTCYP3A4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025085689-A1 | EXTRACELLULAR SMALL MOLECULE ACTIVATORS TARGETING BESTROPHIN CHANNELS FOR DISEASE TREATMENT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-04-24 | — | — | WO | claimed |
| WO-2025085689-A1 | EXTRACELLULAR SMALL MOLECULE ACTIVATORS TARGETING BESTROPHIN CHANNELS FOR DISEASE TREATMENT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-04-24 | — | — | WO | disclosed |
| US-10696659-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-9822076-B2 | Kinase inhibitor | RESPIVERT LIMITED (GB) | 2017-11-21 | — | — | US | disclosed |
| US-20170029378-A1 | KINASE INHIBITOR | OXULAR ACQUISITIONS LIMITED (GB) | 2017-02-02 | — | — | US | disclosed |
| US-9499486-B2 | Kinase inhibitor | RESPIVERT LIMITED (GB) | 2016-11-22 | — | — | US | disclosed |
| US-20160096805-A1 | KINASE INHIBITOR | OXULAR ACQUISITIONS LIMITED (GB) | 2016-04-07 | — | — | US | disclosed |
| EP-0792146-A1 | INACTIVATION OF PATHOGENS USING HYDROXYMETHYLAMINES | HEMASURE, INC. (US) | 1997-09-03 | — | — | EP | disclosed |
| WO-1997002028-A1 | INACTIVATION OF PATHOGENS USING HYDROXYMETHYLAMINES | HEMASURE, INC. (US) | 1997-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096805-A1 | KINASE INHIBITOR | SYK, SRC, LYN | KDM4E 2218/4885ALDH1A1 3858/4885MAPT 2874/4885 |
| US-20170029378-A1 | KINASE INHIBITOR | SYK, BTK, LYN | KDM4E 676/4885ALDH1A1 4333/4885MAPT 4178/4885 |
| US-10696659-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ESR2, ESRRG, ESR1 | KDM4E 2689/4885ALDH1A1 430/4885MAPT 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.